Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.31 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27117858 | 1.00 | GRM5 (0.38) | GRM5GLAKMT2APIK3CDPIK3R2 | |
| SCHEMBL31236983 | 0.94 | GRM5 (0.38) | GRM5GLAKMT2APIK3CDPIK3R2 | |
| SCHEMBL27117920 | 0.88 | GRM5 (0.37) | GRM5PIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL27118703 | 0.88 | GRM5 (0.38) | GRM5GLAKMT2APIK3CDPIK3R2 | |
| SCHEMBL30759592 | 0.87 | GRM5 (0.38) | GRM5GLAKMT2APIK3CDPIK3R2 | |
| SCHEMBL27119377 | 0.87 | GRM5 (0.38) | GRM5GLAKMT2APIK3CDPIK3R2 | |
| SCHEMBL30759519 | 0.85 | GRM5 (0.36) | GRM5GLAKMT2APIK3CDPIK3R2 | |
| SCHEMBL27118043 | 0.85 | GRM5 (0.36) | GRM5GLAKMT2APIK3CDPIK3R2 | |
| SCHEMBL31758931 | 0.85 | GRM5 (0.37) | GRM5 | |
| SCHEMBL27152593 | 0.85 | GRM5 (0.37) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008783-A1 | MODULATORS OF FSHR AND USES THEREOF | GEDEON RICHTER PLC (HU) | 2026-01-08 | — | — | US | disclosed |
| EP-4577206-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | Celmatix Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008783-A1 | MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | GRM5 222/4885GLA 3157/4885KMT2A 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.